MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
69.06
+0.21 (+0.31%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close68.85
Open68.78
Bid68.90 x 900
Ask69.28 x 2200
Day's Range68.70 - 69.24
52 Week Range52.83 - 69.24
Volume7,847,116
Avg. Volume9,337,228
Market Cap183.667B
Beta1.10
PE Ratio (TTM)142.39
EPS (TTM)0.49
Earnings DateOct 25, 2018
Forward Dividend & Yield1.92 (2.88%)
Ex-Dividend Date2018-09-14
1y Target Est70.67
Trade prices are not sourced from all markets
  • Reuters2 days ago

    (OFFICIAL)-UPDATE 2-Japan's Eisai sets price tag of about $17,000 on liver cancer drug (Aug. 16)

    Japan's Eisai Co Ltd said on Thursday it would price its cancer drug Lenvima at about $17,000 for a month's supply before discounts, after the U.S. Food and Drug Administration approved its use in patients with a common form of liver cancer. The drug was approved as the first therapy in over a decade in the United States to treat previously untreated patients with an advanced or intermediate stage of unresectable hepatocellular carcinoma (HCC). "The price at which the recommended starting dose of Lenvima for unresectable HCC will be sold to wholesalers, excluding discounts, is $16,970 for a 30-day supply," Eisai told Reuters.

  • A Closer Look at Allergan’s Business Segments in Q2 2018
    Market Realist2 days ago

    A Closer Look at Allergan’s Business Segments in Q2 2018

    As we discussed earlier, Allergan (AGN) has restructured its business over the last few years, and it now reports its revenues in three business segments.

  • Merck, Eisai Get FDA Approval for Lenvima Label Expansion
    Zacks2 days ago

    Merck, Eisai Get FDA Approval for Lenvima Label Expansion

    Merck (MRK) and Japanese partner Eisai gains an FDA approval for Lenvima label expansion. The anti-cancer drug receives the regulatory body's nod for the first line treatment of unresectable HCC.

  • 4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight
    InvestorPlace2 days ago

    4 Mega-Cap Stocks to Buy As They’re Thrust Into the Spotlight

    U.S. equities soared on Thursday, reversing a two-week malaise, after Walmart (NYSE:WMT) reported solid results and headlines that China’s Vice Commerce Minister would visit the United States for trade talks in late August. Analysts are looking for earnings of $1.15-per-share on revenues of $10.9 billion.

  • Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication
    Zacks2 days ago

    Pharma Stock Roundup: Blow for Bayer, FDA Nod for MRK Cancer Drug in New Indication

    Bayer's (BAYRY) Monsanto subsidiary faces $289 million fine in Roundup lawsuit. Merck/Eisai's drug Lenvima gets FDA approval to treat the most common form of liver cancer.

  • Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics
    Market Realist2 days ago

    Mylan’s Q2 Profit Fell against Backdrop of US Market Dynamics

    Mylan reported its second-quarter results on August 8. Mylan had completed a $1.0 billion share repurchase program at the beginning of 2018, the benefits of which are reflected in its adjusted EPS growth. In the second quarter, Mylan’s gross profit fell ~40% YoY to $962.5 million.

  • A Performance Overview of Bausch’s Diversified Products Business
    Market Realist2 days ago

    A Performance Overview of Bausch’s Diversified Products Business

    Bausch Health Companies’ (BHC) Diversified Products segment reported net revenue of $336 million in the second quarter compared to $461 million in the second quarter of 2017, a ~27% YoY (year-over-year) fall.

  • Reuters2 days ago

    FDA approves Bristol-Myers' Opdivo for small cell lung cancer

    Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy. The drug competes with Merck & Co's Keytruda and belongs to a class of treatments that work by activating the immune system to attack tumors. Both treatments have racked up approvals for indications, including melanoma, lung cancer and head and neck cancer.

  • A Look at Allergan’s Valuation on August 16
    Market Realist2 days ago

    A Look at Allergan’s Valuation on August 16

    Allergan (AGN) is a leading specialty pharmaceutical company focused on developing, manufacturing, and commercializing pharmaceutical and biological products.

  • Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management
    PR Newswire2 days ago

    Healthy Interactions and Merck Announce Launch of Digital Health Platform Designed to Enhance Patient Engagement in Diabetes Management

    KENILWORTH, N.J., Aug. 17, 2018 /PRNewswire/ -- Healthy Interactions, a global leader in health education, in collaboration with Merck (MRK), known as MSD outside the United States and Canada, today announced the launch of map4health™ – a digital platform and mobile application in the U.S. that was designed to help facilitate and enhance communications between diabetes patients and educators. This technology was developed as an extension of the Journey for Control collaboration between Healthy Interactions and Merck, and will make its debut today at the 2018 American Association of Diabetes Educators (AADE) Annual Conference in Baltimore.

  • PR Newswire2 days ago

    Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-Line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

    - Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC - Marks second approval under Eisai-Merck global ...

  • Reuters2 days ago

    WHO expects more Ebola cases in Congo, can't reach no-go areas

    The World Health Organization (WHO) said on Friday that it could not be certain that it had identified all people exposed to the deadly Ebola virus in the Democratic Republic of Congo's North Kivu region, where insecurity prevents aid workers from reaching some areas. More than 500 people have been vaccinated so far against the disease in Congo's latest outbreak, marked by a total of 78 confirmed and probable cases including 44 deaths, it said.

  • Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
    PR Newswire3 days ago

    Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)

    - Approval was based on REFLECT, the first-ever positive Phase 3 trial against an active comparator in previously untreated patients with unresectable HCC - Marks second approval under Eisai-Merck global ...

  • Gauging Analysts’ Expectations for Novavax and Peers in August
    Market Realist3 days ago

    Gauging Analysts’ Expectations for Novavax and Peers in August

    Novavax (NVAX) is a clinical-stage biotechnology company focused on bringing to market recombinant nanoparticle vaccines and adjuvants. Novavax makes use of its proprietary recombinant nanoparticle vaccine technology and saponin-based adjuvant technology to develop vaccine candidates that target different infectious diseases, such as the respiratory syncytial virus and influenza. Novavax has entered into a key grant agreement with the Bill and Melinda Gates Foundation (or BMGF), which is the current source of its revenue.

  • Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?
    Market Realist3 days ago

    Mylan’s North America Sales Down 22% in Q2 2018: What’s Next?

    The company missed Wall Street analysts’ sales estimate of $2.96 billion for the second quarter. The company’s sales have seen YoY declines for the last three quarters. The company is facing intense competition for its EpiPen injectable and the challenging US market dynamics pressuring pricing.

  • Pain Therapeutics' Shares Rally on Alzheimer's Study Grant
    Zacks3 days ago

    Pain Therapeutics' Shares Rally on Alzheimer's Study Grant

    Pain Therapeutics (PTIE) receives grant of $3.2 million from National Institutes of Health to support development of its Alzheimer's disease candidate, PTI-125.

  • MYL Stock Down ~3% since Its Q2 2018 Results on August 8
    Market Realist3 days ago

    MYL Stock Down ~3% since Its Q2 2018 Results on August 8

    The closing price for Mylan (MYL) stock on August 10 was $37.21, and its market capitalization stood at $19.2 billion. The stock registered its 52-week high of $47.82 on January 23 and its 52-week low of $29.39 on August 15, 2017. Currently, MYL stock is trading above its 50-day moving average of $36.80 but below its 200-day moving average of $39.52. On August 8, MYL stock had declined as much as 7.2% on disappointing second-quarter results that missed analysts’ estimates.

  • Most Analysts Are Optimistic about Vertex Pharmaceuticals
    Market Realist3 days ago

    Most Analysts Are Optimistic about Vertex Pharmaceuticals

    How Is Vertex Pharmaceuticals Positioned in August? On February 12, the FDA approved Vertex Pharmaceuticals’ (VRTX) Symdeko, which is the company’s third cystic fibrosis drug in the US market. Symdeko continues to witness a strong launch in the US market, and demand has risen across the entire range of eligible patients.

  • Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results
    Market Realist3 days ago

    Analysts Cut Target Prices on MYL Stock after Its Q2 2018 Results

    Myan (MYL) reported its second-quarter earnings on August 8. For brief highlights, please read Mylan Stock Falls on Q2 Results: Misses Estimates, Cuts Outlook. Following its weak second-quarter performance, multiple brokerages updated their recommendations and target prices on MYL stock, which we’ll discuss in this article.

  • Reuters3 days ago

    Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance

    Pfizer (PFE.N) has agreed to pay German biotech firm BioNTech up to $425 million (£334.33 million) in an alliance to develop more effective influenza jabs, the latest among several major pharma companies to bank on a promising new genetic approach. Privately-held BioNTech will receive $120 million upfront plus up to $305 million depending on certain development achievements as well as tiered royalties on futures sales in the double-digit percentage range, the two companies said in a statement on Thursday. Mainz-based BioNTech, valued at $2.3 billion in a January financing round, is specialising in so-called messenger RNA (mRNA) molecules that instruct human cells to produce therapeutic proteins or to launch an immune response.

  • Investor's Business Daily4 days ago

    FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%

    FANG stocks were down sharply in afternoon trading Wednesday, with shares of Netflix and Google parent Alphabet down more than 2%.

  • Agenus (AGEN) Delivering Well on Its Pipeline Candidates
    Zacks4 days ago

    Agenus (AGEN) Delivering Well on Its Pipeline Candidates

    We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.

  • Reuters5 days ago

    Congo deploys experimental Ebola treatment as cases rise

    GOMA, Democratic Republic of Congo/GENEVA, Aug 14 (Reuters) - D emocratic Republic of Congo has started using the experimental mAb114 Ebola treatment to counter the latest flare-up of the virus, health officials said on Tuesday, the first time it has been deployed against an active outbreak. Forty-two people are believed to have died from the haemorrhagic fever in Congo's tenth Ebola outbreak since it was discovered in the 1970s. In all, there have been 66 cases to date, including 39 confirmed and 27 probable, the health ministry said on Tuesday evening, an increase of nine confirmed cases since Monday.

  • Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018
    Market Realist5 days ago

    Why GlaxoSmithKline’s Vaccines Revenue Grew in Q2 2018

    GlaxoSmithKline’s (GSK) Vaccines segment includes its influenza, meningitis, shingles, and established vaccines. The segment’s revenue grew 13% YoY (year-over-year) to ~1.3 billion British pounds in Q2 2018, as a result of 16% operating revenue growth and a 3% impact by foreign exchange. The chart below shows the segment’s revenue since the first quarter of 2017.